RedHill Biopharma Ltd. Announces a Successful Pivotal Bioequivalence Trial with RHB-102 for the Prevention of Nausea and Vomiting in Cancer Patients

Published: Apr 18, 2012

TEL AVIV, Israel--(BUSINESS WIRE)--RedHill Biopharma Ltd. (TASE: RDHL), an emerging Israeli biopharmaceutical company focusing primarily on development of late clinical-stage (Phase II/III), new formulations and combinations of existing drugs, announces positive results in an advanced bioequivalence clinical trial with RHB-102 for the prevention of nausea and vomiting in cancer patients. RedHill intends to approach the FDA in the coming weeks to request a Pre-NDA meeting to discuss US marketing approval pathway.

Back to news